TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 168 filers reported holding TURNING POINT THERAPEUTICS I in Q3 2020. The put-call ratio across all filers is 1.01 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $312,857,000 | +197.8% | 4,157,552 | +6.2% | 0.01% | +350.0% |
| Q1 2022 | $105,067,000 | -43.2% | 3,913,128 | +0.9% | 0.00% | -50.0% |
| Q4 2021 | $184,949,000 | -28.0% | 3,877,339 | +0.3% | 0.00% | -33.3% |
| Q3 2021 | $256,908,000 | -11.0% | 3,867,337 | +4.5% | 0.01% | -14.3% |
| Q2 2021 | $288,797,000 | -17.3% | 3,701,567 | +0.2% | 0.01% | -22.2% |
| Q1 2021 | $349,278,000 | -16.7% | 3,692,540 | +7.3% | 0.01% | -25.0% |
| Q4 2020 | $419,221,000 | +66.8% | 3,440,460 | +19.6% | 0.01% | +50.0% |
| Q3 2020 | $251,375,000 | +39.8% | 2,877,460 | +3.4% | 0.01% | +33.3% |
| Q2 2020 | $179,765,000 | +92.8% | 2,783,183 | +33.3% | 0.01% | +50.0% |
| Q1 2020 | $93,256,000 | -23.8% | 2,088,121 | +6.3% | 0.00% | 0.0% |
| Q4 2019 | $122,414,000 | +350.6% | 1,965,234 | +172.0% | 0.00% | +300.0% |
| Q3 2019 | $27,169,000 | +53.4% | 722,566 | +66.0% | 0.00% | 0.0% |
| Q2 2019 | $17,712,000 | – | 435,180 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 708,233 | $44,116,000 | 18.91% |
| Corriente Advisors, LLC | 285,000 | $17,753,000 | 9.54% |
| Cormorant Asset Management, LP | 3,396,650 | $211,577,000 | 8.44% |
| Opaleye Management Inc. | 340,500 | $21,210,000 | 4.16% |
| Orbimed Advisors | 2,745,327 | $171,006,000 | 2.44% |
| Parkman Healthcare Partners LLC | 101,434 | $6,318,000 | 1.82% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,000 | $2,179,000 | 0.78% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 366,000 | $22,798,000 | 0.73% |
| Artal Group S.A. | 300,000 | $18,687,000 | 0.72% |
| DAFNA Capital Management LLC | 30,408 | $1,894,000 | 0.65% |